

Meditation and Coronary Heart Disease: A Review of the Current Clinical Evidence

Indranill Basu Ray, MD,¹ Arthur R. Menezes, MD,² Pavan Malur, MD,² Aimee E. Hiltbold, MD,¹
John P. Reilly, MD,³ Carl J. Lavie, MD^{3,4,5}

¹Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA

²Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA

³Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA

⁴Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA

⁵The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA

ABSTRACT

Background: Chest pain from coronary heart disease (CHD) accounts for more than 8 million emergency department visits every year in the United States, emphasizing the need for cardiovascular (CV) interventions to help reduce this high number. Meditation—a state of contemplation, concentration, and reflection—has the potential to help decrease CV disease.

Methods: This article reviews the available data regarding the effects of meditation on various aspects of CV health.

Results: During the past few decades, multiple studies have demonstrated the beneficial effects of meditation on various CV risk factors. In addition to decreasing CV mortality, meditation has also been shown to improve conditions such as hypertension, type 2 diabetes mellitus, dyslipidemia, and high cortisol levels. Still unclear is how current medical therapies impact overall CHD in comparison to meditation techniques.

Conclusion: Prospective trials are needed to study the effects of meditation on CV risk factors, to provide guidelines for daily meditation practice, and to determine the efficacy of meditation compared to current pharmacologic therapies.

Address correspondence to
Indranill Basu Ray, MD
Tulane Heart and Vascular Institute
Tulane University School of Medicine
1415 Tulane Ave.
New Orleans, LA 70112
Tel: (504) 988-5263
Email: ibasuray@tulane.edu

Keywords: Cardiovascular disease, coronary disease, meditation, mind-body therapies

The authors have no financial or proprietary interest in the subject matter of this article.

INTRODUCTION

Meditation is a state of contemplation, concentration, and reflection that originated thousands of years ago as a practice that improves spiritual and emotional well-being. This discipline teaches the practitioner to examine thoughts, feelings, and sensations in a nonjudgmental fashion with the goals of achieving a state of inner calmness, physical relaxation, and psychological balance (Figure).

Various types of meditation are used today. Mantra meditation primarily involves the repetition of words that have phonetic significance, whereas mindfulness meditation generally refers to practices that cultivate awareness and requires paying attention to the present moment. Yoga includes a group of techniques incorporating postures, breath control, and meditation that originated in India. Tai chi and qigong are meditation practices related to Chinese martial arts and traditional Chinese medicine.

Chest pain from coronary heart disease (CHD) accounts for more than 8 million emergency room (ER) visits every year in the United States.¹ Each year, patients presenting with symptoms suggestive of acute coronary syndrome and myocardial infarction (MI) account for as many as 10% of hospital ER cases and up to 25% of all admissions.^{2,3} These numbers represent a considerable burden on healthcare resources, as the cost of treating these patients is approximately \$286 billion annually, or roughly 17% of healthcare expenditures,⁴ emphasizing the need for cardiovascular (CV) interventions such as meditation to help alleviate this problem.

During the past few decades, awareness of the application of meditation or other forms of mind-body therapy in the healthcare setting has increased. Multiple studies have demonstrated the beneficial effects of meditation on various aspects of CV health




Figure. The effects of meditation on the body.

(Table). This article reviews the available data and discusses avenues for future research.

PSYCHOLOGICAL RISK FACTORS AND CHD

During the past 50 years, many studies have established a correlation between psychological risk factors (anxiety, depression, and hostility) and CHD.⁵ Roest et al showed that depression is independently associated with CV mortality.⁶ Substantial evidence suggests that anxiety⁷ and hostility⁸ negatively impact CV health.

The mechanism behind these associations, however, is not clear and is likely multifactorial. Psychological stress (PS) has multiple implications in coronary artery disease that can be categorized into behavioral mechanisms and direct pathophysiologic mechanisms.⁹ Behavioral mechanisms are demonstrated when increased PS increases the frequency of negative practices, such as alcoholism, smoking, poor diet, and patient medical noncompliance.¹⁰ Additionally, elevated PS contributes to direct pathophysiologic processes that increase the risk of coronary artery disease. Chronic increases in PS

Table. Benefits of Meditation

-
1. Improvement in negative mood and depression symptoms
 2. Improvement in fatigue
 3. Improvement in blood pressure
 4. Decreased insulin resistance
 5. Improvement in lipid profiles
-

have been implicated in significant impairment of platelet function, including enhanced platelet reactivity and release of platelet products such as platelet factor 4 and β -thromboglobulin.^{11,12} In animal models, most notably the work done with the *Macaca fascicularis* monkey, chronic PS has been clearly demonstrated to lead to atherosclerosis exacerbation, endothelial dysfunction, and even necrosis.¹³ Kaplan et al postulated that this accelerated atherosclerosis phenomenon was secondary to upregulation of the sympathetic nervous system and excess catecholamines.¹³ Further review reveals that chronic PS is associated with elevated cortisol levels, ovarian dysfunction, and excessive adrenergic activation, all of which herald accelerated atherosclerosis.⁹

While chronic PS increases the risk for developing coronary artery disease, acute PS can trigger MI, arrhythmogenicity, and coronary vasoconstriction.¹⁴ Additionally, acute PS can activate platelet function and promote endothelial dysfunction, both of which can culminate in adverse cardiac events. A 2012 review of the medical literature demonstrated that acute PS can increase sympathetic output, impair endothelial function, and create a hypercoagulable state.¹⁵ These changes have the potential to allow plaque rupture and precipitate intraluminal thrombosis, resulting in MI or sudden death.

The literature suggests that PS affects the autonomic nervous system by increasing catecholamines (such as norepinephrine) and suppressing vagal tone. PS may lead to reduced heart rate (HR) variability, increased resting HR, and delayed postexercise HR recovery.^{16,17} In addition, PS may lead to inflammation, oxidative stress, and abnormal coronary artery tone,¹⁸ as well as platelet activation.¹⁹ PS can also increase CV work and hemodynamic shear stress.¹⁶ All these factors increase the risk of CV events.

Studies have shown that meditation practices have a beneficial effect on psychological risk factors.²⁰⁻²² A study published in 2010 enrolled 42 volunteers to evaluate the effects of progressive self-focus meditation.²³ Participants were divided into 2 groups: 1 that participated in weekly 1-hour training sessions for 5 weeks and 1 waiting-list control group. After 5 weeks, the meditation group had a significant depression score reduction and an increase in

attention compared with the control group. Zeidan et al evaluated the benefits of brief mindfulness meditation sessions on mood and CV variables such as HR and blood pressure (BP) compared to sham meditation.²⁴ The study included 82 undergraduate students (34 males and 48 females) with no prior meditation experience. They participated in 3 training sessions for mindfulness meditation or sham mindfulness meditation, or they were randomized to a control group. The study concluded that meditation intervention was more effective at reducing negative mood, depression, fatigue, confusion, and HR compared to the sham and control groups.

A study evaluating 41 participants who had sustained acute coronary syndrome in the previous 6-18 months assessed a 4-day spiritual retreat's effects on depression and other measures of well-being compared to a lifestyle change program and a control group (usual cardiac care).²⁵ The spiritual retreat included guided imagery, meditation, drumming, journal writing, and nature-based activities. The lifestyle program included nutrition education, exercise, and stress management. Both retreat groups received follow-up phone coaching twice a week for 3 months. At baseline, the spiritual retreat group had the highest depression scores, but this group had significantly lower depression scores at all post-intervention time points ($P \leq 0.002$). Although several measures improved in all 3 groups by 6 months, the spiritual retreat group had immediate improvement after the retreat. This result was maintained for the duration of the study over 3 months.²⁵

In 2012, Barnes and Orme-Johnson published an update on a specific form of meditation known as transcendental meditation (TM),²⁶ a practice that has been shown to reduce sympathetic nervous system activation. Dillbeck and Orme-Johnson reported that acute reductions in respiratory rate and plasma lactate occur during TM practice while control subjects sitting with their eyes closed have increased basal skin resistance.²⁷ Additionally, the subjects practicing TM had a lower baseline HR and respiratory rate, a lower plasma lactate level, and spontaneous skin resistance responses outside of meditation.²⁷

Delui et al studied meditation in patients with cardiovascular disease and depression.²⁸ The 45 patients were randomly assigned to 3 groups: relaxation, meditation, or control. After completing the Beck depression scale and a self-assessment of anxiety, patients underwent a series of 10 sessions of physical muscle relaxation (PMR) or mindfulness meditation, or they received no intervention. Significant reductions in depression scores, systolic blood pressure (SBP), and HR were seen in the meditation group compared with the control group.

Additional studies on the relationship between PS and CHD have been performed on various patient demographics. In a study published in 2014, 5,313 men and women of Hispanic or Latino ethnic backgrounds were scored on their chronic stress burden, based primarily on self-reported stress from domains including finances, work, relationships, health, drug or alcohol use, or additional stressors. After adjusting for sociodemographic, behavioral, and biological risk factors, patients with higher chronic stress scores had an increased prevalence of CHD, stroke prevalence, diabetes, hypertension, and smoking.²⁹

In African American subjects, PS has been determined to play a role in the development of metabolic syndrome. By monitoring endothelial dysfunction, the effect of consciously resting meditation (a sound-based meditation) was compared with a control intervention of health education. Sixty-eight African Americans with metabolic syndrome risk factors were randomized to either the meditation or health education group and monitored for 1 year. Endothelial function was assessed by brachial artery flow-mediated dilation at baseline and at 6 and 12 months. Arterial elasticity, metabolic syndrome risk factors, and psychosocial and behavioral variables were also monitored. After 1 year, flow-mediated dilation improved in the meditation group but was not significantly higher than the flow-mediated dilation in the health education group. No significant change in arterial elasticity was seen in either group. However, most metabolic syndrome risk factors showed beneficial trends in the meditation group only.³⁰

Evidence has linked meditation with reductions in prehypertension. Hughes et al studied mindfulness-based stress reduction (MBSR), an organized protocol of mantra and breathing-focused meditation, in 56 male and female patients with unmedicated prehypertension.³¹ The MBSR group was compared to a group randomized to receive PMR therapy. Participants received 8 weeks of MBSR or PMR sessions administered by a treatment provider and lasting approximately 2.5 hours each week. BP obtained in the clinic was the primary outcome measure. Patients randomized to the MBSR arm exhibited a 4.8 mmHg reduction in SBP and a 1.9 mmHg reduction in diastolic blood pressure (DBP) compared to a 0.7 mmHg reduction in SBP and an increase in DBP in the PMR group.³¹

As stated earlier, psychological risk factors are associated with CHD. Participation in meditation practices has been shown to reduce depression, anxiety, and negative mood and thus may have an indirect positive effect on CV health and well-being. This possibility has led the American Heart Association

to classify TM as a class IIb, level of evidence B alternative approach to lowering BP.³²

MEDITATION AND CHD MORTALITY

One of the earliest studies to evaluate the effects of TM on mortality was published in 1989.³³ Seventy-three residents of 8 homes for the elderly were randomly assigned to a no-treatment group or 1 of 3 treatment groups: the TM program, mindfulness training in active distinction-making, or a relaxation (low mindfulness) program. The mean age of the study population was 81 years. After 3 years, the survival rate was 100% for the TM group and 87.5% for the mindfulness training group in contrast to lower rates for the other groups.³³ A 15-year follow-up of this study demonstrated that the TM group had a lower CV mortality rate than the combined control subjects after adjusting for age, gender, and pretest SBP.³⁴

A metaanalysis of 23 randomized controlled trials determined that the addition of psychosocial interventions, including meditation, breathing exercises, and physical relaxation techniques, in addition to standard cardiac rehabilitation regimens improved outcomes among patients with CHD.³⁵ The metaanalysis evaluated a total of 3,180 participants—2,024 patients who received psychosocial treatment vs 1,156 control subjects. Linden et al observed in this analysis that psychosocially treated patients showed enhanced reductions in psychological distress, SBP, HR, cholesterol levels, and blood pressure compared to the control group. Furthermore, patients who did not receive psychosocial treatment showed greater mortality and adverse CV event rates during the first 2 years of follow-up with a log-adjusted odds ratio of 1.70 for mortality (95% confidence interval [CI], 1.09-2.64).³⁵

Another metaanalysis of 37 studies evaluated the effects of psychoeducational programs.³⁶ The analysis showed that these programs resulted in a 34% reduction in CV mortality, a 29% reduction in recurrence of MI, and significant positive effects on BP, cholesterol, body weight, smoking behavior, physical exercise, and eating habits ($P < 0.025$).

A pooled analysis combined data from a study of 77 white American men and women (mean age 81 years) with data on 125 African American men and women (mean age 66 years) from another randomized trial.³⁷ Mean follow-up was 7.6 ± 3.5 years. Compared with combined controls, the TM group showed a 30% decrease in the rate of CV mortality (relative risk 0.70, $P = 0.045$) and a 23% reduction in all-cause mortality (relative risk 0.77, $P = 0.0399$). These results suggest that the prevention and control of high BP through TM may contribute to decreased mortality from CV causes in elderly patients who have systemic hypertension.

In a controlled trial, 201 African American men and women with CHD were randomized to a TM program or a health education group.³⁸ The primary endpoint was all-cause mortality, MI, or stroke. During the 5.4 year follow-up, the TM group had a 48% risk reduction in the primary endpoint (hazard ratio 0.52; 95% CI, 0.29-0.92; $P=0.025$). The data also demonstrated reductions of 4.9 mmHg in SBP (95% CI, 8.3-1.5 mmHg; $P=0.01$) and anger expression ($P<0.05$ for all scales).

Jayadevappa et al analyzed 23 African American patients hospitalized for congestive heart failure who were randomly assigned to a program of either TM or routine health education.³⁹ After 6 months, the TM group had a significant increase in their 6-minute walk distance as well as improvement in depression scores and quality of life measures. Throughout the 6-month study period, the meditation group had a reduced number of hospitalizations compared to the health education group, indicating the possible mitigation of symptoms.

Although the data suggest a beneficial relationship between meditation and mortality, further studies are needed to assess the effects of meditation on mortality, especially among patients after MI and patients with congestive heart failure.

MEDITATION AND CV RISK FACTORS

During the past few decades, the effects of meditation on hypertension have been debated, and studies have shown conflicting results. A 1993 metaanalysis involving 1,264 patients attempted to assess the efficacy of cognitive behavioral therapies (such as biofeedback, relaxation, and meditation) on essential hypertension.⁴⁰ Overall, the study concluded that cognitive interventions for essential hypertension are superior to no therapy but not superior to credible sham techniques or to self-monitoring alone.

Another study published in 1995 tested the short-term efficacy of 3 approaches—TM, PMR, or lifestyle modification exercise—on the treatment of mild hypertension in 127 elderly African Americans.⁴¹ The study was a randomized, controlled, single-blind trial with 3 months of follow-up in a primary care, inner-city health center. Groups using mental and physical stress reduction approaches (TM and PMR) were compared with a group using a lifestyle modification education control program and with each other. The primary outcome measures were changes in DBP and SBP from baseline to final follow-up, measured by blinded observers. Adjusted for significant baseline differences and compared with the control, TM reduced SBP by 10.7 mmHg ($P<0.0003$) and decreased DBP by 6.4 mmHg ($P<0.0005$). PMR lowered SBP by 4.7 mmHg ($P=0.0054$) and DBP by 3.3 mmHg ($P<0.02$). The reductions in the TM group were

significantly greater than in the PMR group for both SBP ($P=0.02$) and DBP ($P=0.03$).

A 2008 metaanalysis looked at randomized controlled trials through 2006, comparing BP responses to TM to a control group. The analysis included 9 randomized controlled trials with subjects ranging in age from adolescent (mean age 16 years) to senior (mean age 81 years), including normotensive, prehypertensive, and hypertensive individuals meeting eligibility criteria.⁴² Anderson et al found that the TM program lowered SBP an average of 4.7 mmHg and DBP 3.2 mmHg compared with control groups. Subgroup analyses of the hypertensive groups and high-quality studies showed similar BP reductions in all groups.⁴²

Rainforth et al identified 107 studies on the effects of stress reduction programs on BP, including 17 trials with 23 treatment comparisons and 960 participants with elevated BP.⁴³ The stress reduction programs included relaxation, meditation, and biofeedback. Overall, no significant decrease in BP was seen among patients who underwent biofeedback, PMR, or stress management. However, the analysis showed a significant ($P=0.002/0.02$) SBP decrease of 5 mmHg and a 2.8 mmHg decrease in DBP among subjects who practiced TM.

Gregoski et al evaluated the effect of breathing awareness meditation (BAM), Botvin LifeSkills Training, and health education control on ambulatory BP and sodium excretion in African American adolescents.⁴⁴ They found significant group differences for changes in overnight SBP and DBP and HR during the 24-hour period and during school hours. Participants in the BAM treatment group exhibited the greatest overall decreases on these measures (Bonferroni adjusted, $P<0.05$). The researchers concluded that BAM appeared to improve hemodynamic function and may affect sodium handling among African American adolescents who are at increased risk for developing CV diseases.

Meditation has also been linked with beneficial effects on insulin resistance and lipid profiles. A study of 103 subjects with stable CHD examined the efficacy of TM on components of the metabolic syndrome and CHD.⁴⁵ Main outcome measures included BP, lipoprotein profiles, and insulin resistance. The study demonstrated that the TM group had beneficial changes in adjusted SBP (-3.4 ± 2.0 vs 2.8 ± 2.1 mmHg; $P=0.04$), insulin resistance (-0.75 ± 2.04 vs 0.52 ± 2.84 ; $P=0.01$), and HR variability (0.10 ± 0.17 vs -0.50 ± 0.17 high-frequency power; $P=0.07$) compared with the control group. However, no significant decreases in levels of total cholesterol, lipoproteins, and high-sensitivity C-reactive protein were seen, perhaps because of the high prevalence

of statin use and near-optimal low-density lipoprotein cholesterol levels.

Cooper and Aygen compared 12 patients with hypercholesterolemia who regularly practiced meditation with 11 control subjects who did not practice meditation and found a 10% ($P < 0.005$) reduction in fasting serum cholesterol levels in those who practiced meditation during a 13-month period.⁴⁶ Another study demonstrated the postprandial hypoglycemic effect of sitting breathing meditation exercise on 50 patients with type 2 diabetes mellitus and a mean age of 63.1 years.⁴⁷ Participants' levels of postprandial plasma glucose were significantly reduced by 19.26 ± 30.99 mg/dL, ($P < 0.001$) at the second visit and by 17.64 ± 25.48 mg/dL ($P < 0.001$) at the third week visit.

Another risk factor for CHD is elevated levels of plasma cortisol. In the Edinburgh study that included 919 patients (mean age 67.9) with type 2 diabetes mellitus, elevated plasma cortisol levels were associated with raised fasting glucose and total cholesterol ($P < 0.001$) and with prevalent ischemic heart disease, independent of conventional risk factors.⁴⁸ A study published in 1979 examining cortisol levels in 16 patients who were randomized into TM or control groups did not find any acute inhibitory effects of TM on secretion of rennin, aldosterone, or cortisol in the unstressed state.⁴⁹ However, in the stressed state (following venipuncture), a consistent significant rise in cortisol occurred in the controls, while patients participating in meditation did not show this effect. Michaels et al concluded that chronic practice of TM may not directly influence cortisol in the unstressed state but could blunt the response to stress.⁴⁹

In a study of postmenopausal women with similar risk of CV disease, Walton et al compared cortisol levels in patients who were long-term practitioners of TM with cortisol levels in patients who were not. Sixteen women who practiced TM for a mean of 23 years were matched to 14 controls. Cortisol response to a metabolic stressor (75g of glucose, orally) was tested in saliva and urine. Postglucose cortisol rose significantly faster in the control group than in the TM group. In addition, urinary excretion of cortisol was 3 times higher in the control group.⁵⁰

Despite the numerous studies and metaanalyses of the studies on meditation in its various forms, investigators for the Agency for Healthcare Research and Quality reported that solid conclusions on the effects of meditation practices in healthcare cannot be drawn based on the available evidence.⁵¹ Further research on meditation practices should be conducted with an emphasis on design and implementation, as well as on analysis and result reporting.

FUTURE RESEARCH

Patients with CV risk factors such as hypertension and type 2 diabetes mellitus would likely benefit from meditation. Prospective trials are needed to study the effects of meditation on CV risk factors such as lipid profile, C-reactive protein, type 2 diabetes mellitus, and hypertension. Future studies are also needed to provide guidelines (duration, frequency) for daily use of meditation in everyday life.

It is still unclear how current medical therapies such as statins, beta blockers, and angiotensin-converting enzyme inhibitors impact overall CHD in comparison to meditation therapy. Further studies are needed to examine this effect. While aggressive lifestyle modification augments the beneficial effects of medications, it is still not certain how much benefit meditation as a lifestyle modification will bring to this paradigm of disease prevention or amelioration.

CONCLUSION

Meditation is believed to be efficacious in reducing sympathetic activity, lowering cortisol levels via modulation of the hypothalamic pituitary adrenal pathway, and reducing negative behavioral activity. Studies have shown that in addition to decreasing CV mortality, the beneficial effects of meditation improve conditions such as hypertension, type 2 diabetes mellitus, dyslipidemia, and high cortisol levels. However, future studies on the effects of meditation on health are essential to establish a nonbiased view of this emerging landscape.

REFERENCES

1. Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. *J Am Coll Cardiol*. 2011 Sep 27;58(14):1414-1422.
2. Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. *Natl Health Stat Report*. 2010 Aug 6;(26):1-31.
3. Pinkstaff S, Peberdy MA, Kontos MC, Finucane S, Lavie CJ, Arena R. The influence of referral source on characteristics of patients undergoing cardiac stress testing: emergency department versus outpatient office. *Postgrad Med*. 2011 Mar;123(2):36-41.
4. Menezes AR, Lavie CJ, Milani RV, O'Keefe J, Lavie TJ. Psychological risk factors and cardiovascular disease: is it all in your head? *Postgrad Med*. 2011 Sep;123(5):165-176.
5. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. AHA science advisory. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee to the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care Outcomes Research. *Prog Cardiovasc Nurs*. 2009 Mar;24(1):19-26. Republished from: *Circulation*. 2008 Oct 21;118(17):1768-1775.

6. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. *J Am Coll Cardiol*. 2010 Jun 29;56(1):38-46.
7. Lavie CJ, Milani RV, O'Keefe JH, Lavie TJ. Impact of exercise training on psychological risk factors. *Prog Cardiovasc Dis*. 2011 May-Jun;53(6):464-470.
8. Matthews KA, Gump BB, Harris KF, Haney TL, Barefoot JC. Hostile behaviors predict cardiovascular mortality among men enrolled in the Multiple Risk Factor Intervention Trial. *Circulation*. 2004 Jan 6;109(1):66-70.
9. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation*. 1999 Apr 27;99(16):2192-2217.
10. Ziegelstein RC, Bush DE, Fauerbach JA. Depression, adherence behavior, and coronary disease outcomes. *Arch Intern Med*. 1998 Apr 13;158(7):808-809.
11. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. *Am J Psychiatry*. 1996 Oct;153(10):1313-1317.
12. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. *Biol Psychiatry*. 1997 Aug 15;42(4):290-295.
13. Kaplan JR, Manuck SB, Clarkson TB, Lusso FM, Taub DM. Social status, environment, and atherosclerosis in cynomolgus monkeys. *Arteriosclerosis*. 1982 Sep-Oct;2(5):359-368.
14. Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of the coronary arteries to mental stress. *N Engl J Med*. 1991 Nov 28;325(22):1551-1556.
15. Schwartz BG, French WJ, Mayeda GS, et al. Emotional stressors trigger cardiovascular events. *Int J Clin Pract*. 2012 Jul;66(7):631-639.
16. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. *Mayo Clin Proc*. 2002 Jan;77(1):45-54.
17. Suarez EC. Plasma interleukin-6 is associated with psychological coronary risk factors: moderation by use of multivitamin supplements. *Brain Behav Immun*. 2003 Aug;17(4):296-303.
18. Boltwood MD, Taylor CB, Burke MB, Grogin H, Giacomini J. Anger report predicts coronary artery vasomotor response to mental stress in atherosclerotic segments. *Am J Cardiol*. 1993 Dec 15;72(18):1361-1365.
19. Markovitz JH. Hostility is associated with increased platelet activation in coronary heart disease. *Psychosom Med*. 1998 Sep-Oct;60(5):586-591.
20. Saeed SA, Antonacci DJ, Bloch RM. Exercise, yoga, and meditation for depressive and anxiety disorders. *Am Fam Physician*. 2010 Apr 15;81(8):981-986.
21. Mathew KL, Whitford HS, Kenny MA, Denson LA. The long-term effects of mindfulness-based cognitive therapy as a relapse prevention treatment for major depressive disorder. *Behav Cogn Psychother*. 2010 Oct;38(5):561-576.
22. Goldin PR, Gross JJ. Effects of mindfulness-based stress reduction (MBSR) on emotion regulation in social anxiety disorder. *Emotion*. 2010 Feb;10(1):83-91.
23. Leite JR, Ornellas FL, Amemiya TM, et al. Effect of progressive self-focus meditation on attention, anxiety, and depression scores. *Percept Mot Skills*. 2010 Jun;110(3 Pt 1):840-848.
24. Zeidan F, Johnson SK, Gordon NS, Goolkasian P. Effects of brief and sham mindfulness meditation on mood and cardiovascular variables. *J Altern Complement Med*. 2010 Aug;16(8):867-873.
25. Warber SL, Ingerman S, Moura VL, et al. Healing the heart: a randomized pilot study of a spiritual retreat for depression in acute coronary syndrome patients. *Explore (NY)*. 2011 Jul-Aug;7(4):222-233.
26. Barnes VA, Orme-Johnson DW. Prevention and treatment of cardiovascular disease in adolescents and adults through the Transcendental Meditation® program: a research review update. *Curr Hypertens Rev*. 2012 Aug;8(3):227-242.
27. Dillbeck MC, Orme-Johnson DW. Physiological differences between Transcendental Meditation and rest. *Am Psychol*. 1987 Sep;42(9):879-881.
28. Delui MH, Yari M, Khouyinezhad G, Amini M, Bayazi MH. Comparison of cardiac rehabilitation programs combined with relaxation and meditation techniques on reduction of depression and anxiety of cardiovascular patients. *Open Cardiovasc Med J*. 2013 Oct 18;7:99-103.
29. Gallo LC, Roesch SC, Fortmann AL, et al. Associations of chronic stress burden, perceived stress, and traumatic stress with cardiovascular disease prevalence and risk factors in the Hispanic Community Health Study/Study of Latinos Sociocultural Ancillary Study. *Psychosom Med*. 2014 Jul-Aug;76(6):468-475.
30. Vaccarino V, Kondwani KA, Kelley ME, et al. Effect of meditation on endothelial function in Black Americans with metabolic syndrome: a randomized trial. *Psychosom Med*. 2013 Jul-Aug;75(6):591-599.
31. Hughes JW, Fresco DM, Myerscough R, van Dulmen MH, Carlson LE, Josephson R. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. *Psychosom Med*. 2013 Oct;75(8):721-728.
32. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. *Hypertension*. 2013 Jun;61(6):1360-1383.
33. Alexander CN, Langer EJ, Newman RI, Chandler HM, Davies JL. Transcendental meditation, mindfulness, and longevity: an experimental study with the elderly. *J Pers Soc Psychol*. 1989 Dec;57(6):950-964.
34. Alexander CN, Barnes VA, Schneider RH, et al. A randomized controlled trial of stress reduction on cardiovascular and all-cause mortality in the elderly: results of 8 and 15 year follow-ups [abstract]. *Circulation*. 1996;93(suppl):P629.
35. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. *Arch Intern Med*. 1996 Apr 8;156(7):745-752. Erratum in: *Arch Intern Med*. 1996 Nov 11;156(20):2302.
36. Dusseldorp E, van Elderen T, Maes S, Meulman J, Kraaij V. A meta-analysis of psychoeducational programs for coronary heart disease patients. *Health Psychol*. 1999 Sep;18(5):506-519.
37. Schneider RH, Alexander CN, Staggars F, et al. Long-term effects of stress reduction on mortality in persons > or = 55 years of age with systemic hypertension. *Am J Cardiol*. 2005 May 1;95(9):1060-1064.
38. Schneider RH, Grim CE, Rainforth MV, et al. Stress reduction in the secondary prevention of cardiovascular disease: randomized, controlled trial of transcendental meditation and health education in Blacks. *Circ Cardiovasc Qual Outcomes*. 2012 Nov;5(6):750-758.

39. Jayadevappa R, Johnson JC, Bloom BS, et al. Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. *Ethn Dis*. 2007 Winter;17(1):72-77. Erratum in: *Ethn Dis*. 2007 Summer;17(3):595.
40. Eisenberg DM, Delbanco TL, Berkey CS, et al. Cognitive behavioral techniques for hypertension: are they effective? *Ann Intern Med*. 1993 Jun 15;118(12):964-972.
41. Schneider RH, Staggers F, Alexander CN, et al. A randomized controlled trial of stress reduction for hypertension in older African Americans. *Hypertension*. 1995 Nov;26(5):820-827.
42. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to transcendental meditation: a meta-analysis. *Am J Hypertens*. 2008 Mar;21(3):310-316.
43. Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. *Curr Hypertens Rep*. 2007 Dec;9(6):520-528.
44. Gregoski MJ, Barnes VA, Tingen MS, Harshfield GA, Treiber FA. Breathing awareness meditation and LifeSkills Training programs influence upon ambulatory blood pressure and sodium excretion among African American adolescents. *J Adolesc Health*. 2011 Jan;48(1):59-64.
45. Paul-Labrador M, Polk D, Dwyer JH, et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. *Arch Intern Med*. 2006 Jun 12;166(11):1218-1224.
46. Cooper MJ, Aygen MM. A relaxation technique in the management of hypercholesterolemia. *J Human Stress*. 1979 Dec;5(4):24-27.
47. Chaioponont S. Hypoglycemic effect of sitting breathing meditation exercise on type 2 diabetes at Wat Khae Nok Primary Health Center in Nonthaburi province. *J Med Assoc Thai*. 2008 Jan;91(1):93-98.
48. Reynolds RM, Labad J, Strachan MW, et al. Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *J Clin Endocrinol Metab*. 2010 Apr;95(4):1602-1608.
49. Michaels RR, Parra J, McCann DS, Vander AJ. Renin, cortisol, and aldosterone during transcendental meditation. *Psychosom Med*. 1979 Feb;41(1):50-54.
50. Walton KG, Fields JZ, Levitsky DK, Harris DA, Pugh ND, Schneider RH. Lowering cortisol and CVD risk in postmenopausal women: a pilot study using the Transcendental Meditation program. *Ann N Y Acad Sci*. 2004 Dec;1032:211-215.
51. Ospina MB, Bond K, Karkhaneh M, et al. Meditation practices for health: state of the research. *Evid Rep Technol Assess (Full Rep)*. 2007 Jun;(155):1-263.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.